5 results about "Amyloid beta proteins" patented technology

The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

To provide technology that can be used to inhibit aggregation of β-amyloid protein (Aβ) and microtubule-binding protein Tau, which bring about senile plaque (senile plaque: AP) and neurofibrillary tangle (Neurofibrillary Tangle: NFT).SOLUTION: The present invention provides a protein aggregation inhibitor containing mesostructured particles of calcium hydrogen carbonate as an active ingredient.SELECTED DRAWING: Figure 2

Provided herein are compounds, methods, and compositions for determining whether a patient has a neurological disease or condition, comprising detecting the presence or cumulative mass thereof of a detectable target protein in a tissue or sample of the patient, such as the presence or cumulative mass thereof of amyloid beta protein or phosphorylated tau protein. The detection may comprise contacting the target protein with a compound described herein.

The present disclosure relates to improved peptide immunogen constructs targeting a portion of the Tau protein for use in the treatment and / or prevention of Tau protein pathologies. The present disclosure also relates to improved peptide immunogen constructs targeting a portion of amyloid beta for use in the treatment and / or prevention of tauopathies. The present disclosure also relates to compositions and kits comprising the peptide immunogen constructs, in particular compositions and kits comprising a combination of various peptide immunogen constructs. Also provided herein are methods of making and using the peptide immunogen constructs, as well as antibodies produced by the peptide immunogen constructs. In some aspects, the disclosure relates to compositions comprising a peptide immunogen construct based on a portion of the Tau protein and a peptide immunogen construct based on a portion of the amyloid beta protein, and the use of these peptide immunogen constructs and compositions in methods of treatment.

The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.